


# IMMUNOGEN

ImmunoGen, Inc.  
Investor Relations Department  
830 Winter Street  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## NASDAQ: IMGN

Last Trade:	7.00
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	0.46  (+7.034%)
Day Range	6.45 - 7.10
52-Week Range	1.51 - 7.00
Volume	4,097,439

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyra<sup>®</sup>, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 26, 2017*

[ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia](#)

*May 30, 2017*

[ImmunoGen and Sanofi Amend License Agreements](#)

*May 24, 2017*

[ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference](#)

*May 23, 2017*

[Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen](#)

*May 17, 2017*

[ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Aug 25, 2016*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 4, 2016*

[Quarterly Report \(10-Q\)](#)

*May 4, 2016*

[Quarterly Report \(10-Q\)](#)